Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Clinical Investigation of Safety and Effectiveness of Emerald IPLdevice (Emerald)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03945383
Recruitment Status : Recruiting
First Posted : May 10, 2019
Last Update Posted : June 29, 2021
Sponsor:
Information provided by (Responsible Party):
Philips Healthcare

Brief Summary:

Prospective, multi-center, single-arm, single blinded (Philips hair counter) study in healthy women of skin types I up to and including V.

Safety and efficacy of hair removal with the Emerald IPL-device will be investigated for treatment in face of subjects with ST I - IV and for treatment in face, axilla, bikini area, and legs of subjects with ST V.

In-clinic, the study subjects will undergo twelve IPL-treatments bilaterally at the qualified areas (face and / or axilla, bikini line, and legs) with the Emerald IPL device applied by a device operator.

Hair re-growth in each area will be evaluated separately and across all skin types.

After the 4 bi-weekly treatments, one follow-up visit will be organized two weeks after the 4th treatment. After the completion of the full treatment cycle (12 treatments), subjects will be followed for 1 and 3 months (short-term follow-up) and for 6, 9 and 12 months (long-term follow up).


Condition or disease Intervention/treatment Phase
Hair Removal Device: Treatment with IPL device Not Applicable

Detailed Description:

Hair grows in cyclic phases: anagen, catagen and telogen. These phases impact on how the process of light-based hair removal works. The hair grows during the anagen phase, which has the longest duration in the hair growth cycle. Hair growth ends with the transition from anagen into the catagen phase, a short transition phase to prepare for the resting phase, the telogen, which ends with shedding of the hair and the start of the hair growth cycle. During telogen phase, the hair follicle remains inactive. Each hair follicle is independent and goes through the growth cycle at different times. As presented in table 5 [11], the duration of the growth cycle of the upper lip, axilla and bikini line are different from that of the legs. In general, the telogen and anagen phase's durations of the cycle are longest for the legs (i.e., 24 and 16 weeks, respectively) and the shortest for upper lip (i.e. 6 weeks for both phases). Therefore, hair response to the IPL treatment will be evaluated by body area.

The efficacy of permanent hair reduction will be measured following the definition of permanent hair reduction according to the FDA as follows: "Permanent hair reduction is defined as the long-term, stable reduction in the number of hairs re-growing after a treatment regime, which may include several sessions. The number of hairs re-growing must be stable over time greater than the duration of the complete growth cycle of hair follicles, which varies from four to twelve months according to body location. Permanent hair reduction does not necessarily imply the elimination of all hairs in the treatment area."

In an attempt to promote permanent hair reduction, the aim is to expose all hairs at least once to an IPL flash and therefore treatment will cover the full duration of a hair growth cycle). The longest relevant full hair growth cycle is on the legs (40 weeks, excluding approximately 2 weeks for the catagen phase). Therefore, a treatment duration of 10 months (approximately 38weeks) has been selected: a full IPL treatment cycle consists of 4 initial treatments, once every 2 weeks, followed by 8 maintenance (monthly) treatments, once every 4 weeks. The hair growth cycle on face (upper lip) is the shortest (12 weeks, 6 weeks in anagen, 6 weeks in telogen phases). The initial treatments in 2 weeks interval are expected to be most beneficial for face treatment.

For this study, there are two cohorts for enrollment:

  1. Subjects with Skin Type I-IV for treatment of Face only. (N=53)
  2. Subjects with Skin Type V for treatment of all body areas: Face, Axilla, Bikini line and leg. (N=19)

The visits are as follows:

Screening Visit: The volunteers are screened to identify subjects who meet all of the inclusion and none of the exclusion criteria. Device settings are selected based on skin tone and comfort evaluation..

Visits 1-4 (TX1-TX4): Four treatments and the collection of safety and efficacy data are scheduled to occur every 2 weeks/ 14 days; Visits 5 (Initial Treatment 2wk Follow-up): Safety and efficacy data are collected 2 weeks/ 14 days after 4th treatment to demonstrate hair removal performance 8 weeks after baseline.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 72 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Intervention Model Description: All enrolled subjects will be treated with the investigational device
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Clinical Investigation of Safety and Efficacy of the Emerald IPL Device for Hair Reduction for the Extension of Its Intended Use to Face and to Skin Type V Population
Actual Study Start Date : April 15, 2019
Estimated Primary Completion Date : November 30, 2021
Estimated Study Completion Date : November 30, 2021

Arm Intervention/treatment
Experimental: Treatment with IPL device
The Emerald IPL device is applied by the Investigator or designee to the right and left side of the body. Treatment areas are 2x4 cm2 for the leg and bikini line areas. The entire axilla and face (upper lip) area will be treated due to the small area involved.
Device: Treatment with IPL device
Treatment with IPL device




Primary Outcome Measures :
  1. Proportion of subjects with at least 30% hair reduction relative to baseline at 8 and 10 weeks after baseline and at 1 and 3 months after last treatment [ Time Frame: approximately 13 months ]
    Efficacy of the device will be measured by evaluating the proportion of subjects with >= 30% hair reduction on the face, axilae, bikini area and legs following the intensive treatment phase at 8 and 10 weeks as well as during short term follow up of 1 month and 3 months after the last treatment.


Secondary Outcome Measures :
  1. Safety will be measured by proportion of treatment-emerged, anticipated adverse events, non-anticipated adverse events, serious adverse events and other related reasons for discontinuation. [ Time Frame: Approximately 22 months ]
    The primary safety endpoints include the treatment-emerged, anticipated adverse events, non-anticipated adverse events, serious adverse events and reasons for discontinuation during the treatment of the face, axilae, bikini area and legs with the device as well as during the follow-up period.

  2. Assessment of the subjective satisfaction with the treatment results of the Emerald IPL device for removal of unwanted hair on face, axillae, bikini area, and legs: 5-point Likert satisfaction scale [ Time Frame: Approximately 22 months ]
    Percent of top-two category answers of 5-point Likert satisfaction scale in assessment of subjective satisfaction with the treatment results in all body areas.

  3. Assessment of the acceptance of the Emerald IPL devices for removal of unwanted hair in each body area: Percent of top-two category answers in assessment of acceptance [ Time Frame: Approximately 22 months ]
    Percent of top-two category answers in assessment of acceptance of hair reduction, skin smoothness, and comfort after treatment with Philips investigational IPL devices in all body areas.

  4. Proportion of subjects with at least 30% hair reduction relative to baseline at 6, 9 and 12 months post-final treatment per body area. [ Time Frame: Approximately 22 months ]
    Efficacy of the device will be measured by evaluating the proportion of subjects with >= 30% hair reduction on the face, axilae, bikini area and legs during the long term follow up of 1 month and 3 months after the last treatment.


Other Outcome Measures:
  1. Exploratory Endpoint [ Time Frame: Approximately 18 months ]
    Percent of subjects with the same device setting as Setting Indication by STS device and device setting as result of Test Flash or as result of skin type self-assessment.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Be willing to provide informed consent
  2. Are healthy female subjects, in age of 18-65 years
  3. Have natural body hair color that is dark blonde, brown or black in the designated treatment areas

    3.1. Subjects of ST I-IV - Face group:

    3.1.1 Have Fitzpatrick Skin Type I, II, III, or IV

    3.1.2 Measure melanin value ≤ 375 in the qualifying treatment areas bilateral on upper lip (face)

    3.1.3. Have a minimum of 10 hairs in the 1x2cm2 qualifying treatment areas bilateral on upper lip (face), by visual inspection

    3.2. Subjects of ST V - All body area group:

    3.2.1. Have Fitzpatrick Skin Type V

    3.2.2. Measure melanin value ≤ 553 in the qualifying treatment areas bilateral on upper lip (face), axilla, bikini line, and leg

    3.2.3. Have a minimum of 10 hairs in the 1x2cm2 qualifying treatment areas bilateral on upper lip (face), by visual inspection

    3.2.4.Have a minimum of 24 hairs in each of the 2x4cm2 qualifying treatment areas bilateral on axilla, bikini line, and leg, by visual inspection

  4. Be either post-menopausal or surgically sterilized, or using a medically acceptable form of birth control (e.g., oral contraceptives, IUD, contraceptive implant, barrier methods with spermicide or abstinence, etc.).
  5. Be willing to participate in all study visits
  6. Be willing to refrain from deliberate exposure to strong sun, products or procedures that would cause the skin to become darker in the designated treatment areas during the treatment phase
  7. Be willing to refrain from the use of hair growth inhibitors/accelerators during the course of the study
  8. Be willing to refrain from waxing, depilating or epilating of the axilla, bikini line, leg, and face
  9. Be willing to refrain from using aspirin or NSAIDs (e.g. acetaminophen, ibuprofen, etc.) within 5 days prior to and 5 days after treatment(s) -

Exclusion Criteria:

  1. Have natural body hair color that is white, light blond, or red in the designated treatment areas

    1.1. Subjects of ST I to IV - Face group:

    1.1.1. Have Fitzpatrick Skin Type V or VI

    1.1.2. Measure melanin value higher than 375 in the qualifying treatment areas bilateral on upper lip

    1.1.3. Have fewer than 2 qualifying treatment areas on bilateral on upper lip (face)

    1.2. Subjects of ST V - All body area group:

    1.2.1. Have Fitzpatrick Skin Type I, II, III, IV, or VI

    1.2.2. Measure melanin value higher than 553 in any of the qualifying treatment areas bilateral on the body

    1.2.3. Have fewer than 8 qualifying treatment areas bilateral: 2 in face, 2 in axilla, 2 on bikini line, and 2 on legs

  2. Have a malignant or pre-malignant pigment in the area to be treated
  3. Have scarring or infection of the area to be treated
  4. Have a known history of photosensitivity or use of medication known to induce photosensitivity
  5. Are currently pregnant or lactating or planning be become pregnant in the period of the study, per subject report
  6. Are currently on a daily dose of aspirin or NSAIDs (e.g. acetaminophen, ibuprofen, etc.) or have taken aspirin and/or NSAIDs within 5 days prior to treatment that would reduce or increase the sensation of pain
  7. Are not willing to abstain from the use of products or light exposure that would induce tanning in the treatment areas during the IPL treatment period (first 10 months)
  8. Have a history of immunosuppressive disease (including HIV infection or AIDS)
  9. Are on a anticoagulative medication or thromboembolic condition
  10. Have taken any form of isotretinoin (such as Accutane or Roaccutane etc.) in the last six months
  11. Have an active implantable device such as a pacemaker, neurostimulator or internal defibrillator
  12. Have used waxing or other methods of root hair removal, or photo-epilation in the areas to be treated within 6 months prior to treatment
  13. Have been exposed to strong sunlight or an artificial tanning machine in the area to be treated within 4 weeks of enrolment
  14. Have a tattoo(s), warts, moles, benign skin lesions, dark pigmented areas, permanent make-up etc. in the areas to be treated.
  15. Have eczema, psoriasis, lesions, open wounds or any skin affliction in the areas to be treated
  16. Have a history of keloid scar formation
  17. Have a history of herpes outbreaks in the areas to be treated
  18. Have a history of photosensitive epilepsy
  19. Have a condition related to hormonal changes like polycystic ovarian syndrome (PCOS) or taking drugs leading to hormonal changes resulting in excessive hair growth like hirsutism or idiopathic hirsutism
  20. Have diabetes, or metabolic disease that affects hair growth
  21. Taking immunosuppressive medication(s)
  22. Have a disease related to photosensitivity, such as polymorphic light eruption (PMLE), solar urticaria, porphyria etc.
  23. Have a history of skin cancer, including past basal cell carcinoma and/or squamous cell carcinoma in the areas to be treated
  24. Have a history of any radiation therapy in any of the areas to be treated
  25. Have history of radiation therapy in non-treatment areas within 5 years
  26. Have a history of chemotherapy
  27. Have used hair growth inhibitors and/or accelerators within 6 months preceding enrolment
  28. Have had laser or electrolysis treatment for the removal of hair in the areas to be treated within the last year
  29. Have natural body hair colors of white, grey, light to mid-blond, or red in the areas to be treated
  30. Have bleaching of their body hair in the areas to be treated 6 months prior to study enrolment
  31. Have shaved the areas to be treated within 7 days prior to study enrolment
  32. Participating in other clinical studies prior to, or concurrently with this study, that could be deemed to interfere with full and complete participation in this study - as determined by the site investigator.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03945383


Contacts
Layout table for location contacts
Contact: Pat Olsen 3034753417 pat.olsen@philips.com

Locations
Layout table for location information
United States, Illinois
Great Lakes Clinical Trials Recruiting
Chicago, Illinois, United States, 60640
Contact: Janet Nelson    773-275-3500    jnelson@greatlakesclinicaltrials.com   
Contact: Amber Holst    (773) 275-3500    aholst@greatlakesclinicaltrials.com   
Principal Investigator: Rupal Trivedi, MD         
United States, Virginia
Virginia Clinical Research Not yet recruiting
Norfolk, Virginia, United States, 23502
Contact: Dannielle Benedict    757-625-0151    dbenedict@vcrinc.org   
Contact: Brandy Hartman    757-625-0151    bhartman@vcrinc.org   
Principal Investigator: David Pariser, MD         
Sub-Investigator: Robert Pariser, MD         
Sub-Investigator: Tina Watkins, MD         
Sponsors and Collaborators
Philips Healthcare
Investigators
Layout table for investigator information
Principal Investigator: Rupal Trivedi, M.D. Great Lakes Clinical Trials
Principal Investigator: David Pariser, M.D. Virginia Clinical Research
Publications:
Shamsuddin K et. al, The reliability of Fitzpatrick Skin Type Chart Comparing to Mexameter (Mx 18) in measuring skin color among first trimester, Malaysian Journal of Public Health Medicine 2016, Vol. 16 (3): 59-65

Layout table for additonal information
Responsible Party: Philips Healthcare
ClinicalTrials.gov Identifier: NCT03945383    
Other Study ID Numbers: PC-BEA-Emerald STV&Face-10560
First Posted: May 10, 2019    Key Record Dates
Last Update Posted: June 29, 2021
Last Verified: June 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: Yes
Device Product Not Approved or Cleared by U.S. FDA: Yes
Product Manufactured in and Exported from the U.S.: Yes